Skip to main content
. 2023 Feb 28;9(1):e002676. doi: 10.1136/rmdopen-2022-002676

Figure 3.

Figure 3

Effect of burosumab maintenance on PROs and 6MWT. Data available for 31 participants at BL, 28 at week 48b for WOMAC, 27 at week 48b for BPI-SF and BFI and 16 at week 48b for 6MWT. Analysis weeks in the phase 3 study and open-label extension are indicated by ‘a’ and ‘b’ suffixes, respectively. A decrease in score indicates improvement on the WOMAC, BPI-SF and BFI. An increase in distance indicates improvement on the 6MWT. BPI-SF and BFI data were captured at a single site visit and were not completed as part of a patient diary at weeks 72a and 96a. *p<0.05 for LSM change from BL (generalised estimating equation repeated-measures analysis). Six participants (19%) used an assistive device during the 6MWT at the phase 3 baseline, decreasing to three (10%) at phase 3 week 72a, and one from week 12b. BFI, Brief Fatigue Inventory; BL, baseline; BPI-SF, Brief Pain Inventory short-form; LSM, least squares mean; MCID, minimum clinically important difference; 6MWT, 6-Minute Walk Test; PRO, patient-reported outcome; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.